N@N

ValiMed(TM) Launched in the Middle East by Virtus Trading LLC

  //science-technology.news-articles.net/content/2 .. ed-in-the-middle-east-by-virtus-trading-llc.html
  Published in Science and Technology on Monday, November 16th 2009 at 6:28 GMT by Market Wire

TUCSON, AZ and ABU DHABI, UNITED ARAB EMIRATES--(Marketwire - November 16, 2009) - CDEX Inc. (OTCBB: [ CEXI ]) ([ www.cdexinc.com ]) and Virtus Trading LLC announce that Malcolm Philips, CEO of CDEX, and Anil Pinto, Executive Director at Virtus, recently met with senior officials of health ministries, hospital administrators and pharmacists and conducted seminars on Medication Safety to the medical communities in Abu Dhabi, Dubai, Kuwait and Saudi Arabia as part of the regional launch of the ValiMed™ Medication Validation System. Worldwide studies continue to show that human errors in the compounding of high-risk medications occur frequently and result in permanent harm to patients throughout the world. The seminars focused on actions to minimize mistakes and the ValiMed technological safety net that provides protection for patients, pharmacists and hospitals.

"The message presented in the seminars was very well received and we are confident that the Middle East will be a strong market for ValiMed given current momentum on raising patient care standards across the region," said Mr. Pinto. "We at Virtus and Virtus Al-Essa look forward to a very long and successful association with CDEX."

"It was a privilege to talk to the pharmacy teams in this region, some of the best in the world, and it was reinforced to me that compounding errors and their devastating aftermath know no geographical boundaries," said Mr. Philips. "We are honored to partner with Virtus in bringing the ValiMed technology to hospitals in this region. They share with CDEX and its growing number of ValiMed clients a passion for patient safety."

About CDEX

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, contact Malcolm Philips at [ mphilips@cdex-inc.com ].

About Virtus

Drawing on over 30 years of business experience in Kuwait, and our commitment to the healthcare industry in the Gulf, Virtus Trading LLC was established with the objective of "Making the difference" on a regional basis. Our range of activities involves supplying products, installation, providing application support, clinical support and maintenance for medical and analytical needs. We can deliver complete solutions in facility engineering, providing mechanical piping, furniture, furnishing and equipment. Our ability to undertake this comprehensive range of activities in the region comes from more than 30 years of corporate experience in managing the Al-Essa Group of Companies, a premier company engaged in delivering total solution in the Healthcare and Scientific Sectors in Kuwait. We are proud of our unparalleled reputation for providing quality solutions, the result of a corporate ethos that has won recognition from our valued customers. More information about Al-Essa can be found at [ http://www.alessakuwait.com ].

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "believes," "should," "intends," and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.